 Actions novel antidiabetic agent englitazone hyperglycemic hyperinsulinemic ob/ob mice effects CP englitazone ob/ob mice adipocytes soleus muscles ob/ob mice adipocytes Administration englitazone plasma glucose insulin frank hypoglycemia diabetic nondiabetic lean animals glucose-lowering effect ob/ob mice reduction hyperinsulinemia cessation drug plasma insulin untreated levels plasma glucose days Englitazone mg/kg days plasma glucose mM insulin nM nonesterified fatty acids microM glycerol mM triglycerides g/L cholesterol mM effects single dose Basal insulin-stimulated lipogenesis adipocytes ob/ob mice mg/kg englitazone days lipogenesis cells vehicle-treated controls Treatment ob/ob mice mg/kg defects insulin-stimulated glycolysis glucose glycogenesis basal glucose oxidation glucose isolated soleus muscles Englitazone microM transport adipocytes protein englitazone insulinomimetic insulin-enhancing actions vitro glucose- insulin- triglyceride- cholesterol-lowering properties animal model non-insulin-dependent diabetes NIDDM sulfonylureas little effect new agent beneficial effects reduced risk hypoglycemia patients NIDDM